Literature DB >> 11808820

Hypotension and bradycardia in a healthy volunteer following a single 5 mg dose of olanzapine.

John S Markowitz1, C Lindsay DeVane, David W Boulton, Heidi L Liston, S Craig Risch.   

Abstract

Olanzapine is an atypical antipsychotic medication indicated for the treatment of schizophrenia and other manifestations of psychotic illness. Common side effects include somnolence, constipation, weight gain, and postural hypotension. The authors report a case of hypotension accompanied by bradycardia in a normal, healthy volunteer participating in an olanzapine pharmacokinetic study following a single 5 mg dose. A venous catheter allowed for serial blood sampling of olanzapine concentrations before, during, and after the adverse event. The subject experienced a rapid absorption of the drug and higher than anticipated maximum plasma concentrations. This case suggests that atypical antipsychotics, although generally better tolerated than conventional agents, may still result in untoward reactions that may be partially due to individual differences in drug absorption and metabolism.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11808820     DOI: 10.1177/0091270002042001013

Source DB:  PubMed          Journal:  J Clin Pharmacol        ISSN: 0091-2700            Impact factor:   3.126


  3 in total

1.  A Phase I Open-Label Study to Evaluate the Effects of Rifampin on the Pharmacokinetics of Olanzapine and Samidorphan Administered in Combination in Healthy Human Subjects.

Authors:  Lei Sun; David McDonnell; Miao Yu; Vipul Kumar; Lisa von Moltke
Journal:  Clin Drug Investig       Date:  2019-05       Impact factor: 2.859

2.  Effect of hepatic and renal impairment on the pharmacokinetics of olanzapine and samidorphan given in combination as a bilayer tablet.

Authors:  Lei Sun; Sergey Yagoda; Yangchun Du; Lisa von Moltke
Journal:  Drug Des Devel Ther       Date:  2019-08-22       Impact factor: 4.162

3.  Olanzapine-induced Orthostatic Hypotension.

Authors:  Amlan Kusum Jana; Samir Kumar Praharaj; Nirmalya Roy
Journal:  Clin Psychopharmacol Neurosci       Date:  2015-04-30       Impact factor: 2.582

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.